Cherney B - Search Results

1

Meeting report on protein particles and immunogenicity of therapeutic proteins: filling in the gaps in risk evaluation and mitigation.

Carpenter J, Cherney B, Lubinecki A, Ma S, Marszal E, Mire-Sluis A, Nikolai T, Novak J, Ragheb J, Simak J. Carpenter J, et al. Among authors: cherney b. Biologicals. 2010 Sep;38(5):602-11. doi: 10.1016/j.biologicals.2010.07.002. Epub 2010 Aug 11. Biologicals. 2010. PMID: 20702108

2

Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality.

Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G, Fan YX, Kirshner S, Verthelyi D, Kozlowski S, Clouse KA, Swann PG, Rosenberg A, Cherney B. Carpenter JF, et al. Among authors: cherney b. J Pharm Sci. 2009 Apr;98(4):1201-5. doi: 10.1002/jps.21530. J Pharm Sci. 2009. PMID: 18704929 Free PMC article. No abstract available.

3

Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products.

Li K, Rogers G, Nashed-Samuel Y, Lee H, Mire-Sluis A, Cherney B, Forster R, Yeh P, Markovic I. Li K, et al. Among authors: cherney b. PDA J Pharm Sci Technol. 2015 Sep-Oct;69(5):590-619. doi: 10.5731/pdajpst.2015.01073. PDA J Pharm Sci Technol. 2015. PMID: 26429108

4

Managing uncertainty: a perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins.

Rosenberg AS, Verthelyi D, Cherney BW. Rosenberg AS, et al. J Pharm Sci. 2012 Oct;101(10):3560-7. doi: 10.1002/jps.23244. Epub 2012 Jun 26. J Pharm Sci. 2012. PMID: 22736548

5

Risk mitigation strategies for viral contamination of biotechnology products: consideration of best practices.

Rosenberg AS, Cherney B, Brorson K, Clouse K, Kozlowski S, Hughes P, Friedman R. Rosenberg AS, et al. Among authors: cherney b. PDA J Pharm Sci Technol. 2011 Nov-Dec;65(6):563-7. doi: 10.5731/pdajpst.2011.00820. PDA J Pharm Sci Technol. 2011. PMID: 22294578

6

Scientific considerations for generic synthetic salmon calcitonin nasal spray products.

Lee SL, Yu LX, Cai B, Johnsons GR, Rosenberg AS, Cherney BW, Guo W, Raw AS. Lee SL, et al. Among authors: cherney bw. AAPS J. 2011 Mar;13(1):14-9. doi: 10.1208/s12248-010-9242-9. Epub 2010 Oct 30. AAPS J. 2011. PMID: 21052882 Free PMC article.

7

The FDA's assessment of follow-on protein products: a historical perspective.

Woodcock J, Griffin J, Behrman R, Cherney B, Crescenzi T, Fraser B, Hixon D, Joneckis C, Kozlowski S, Rosenberg A, Schrager L, Shacter E, Temple R, Webber K, Winkle H. Woodcock J, et al. Among authors: cherney b. Nat Rev Drug Discov. 2007 Jun;6(6):437-42. doi: 10.1038/nrd2307. Nat Rev Drug Discov. 2007. PMID: 17633790 Review.

8

Application of quality by design in the control of adventitious viruses: gaps in current processes in the prevention of virus contaminants.

Cherney B. Cherney B. PDA J Pharm Sci Technol. 2011 Nov-Dec;65(6):754-66. doi: 10.5731/pdajpst.2011.00849. PDA J Pharm Sci Technol. 2011. PMID: 22294609

9

Hurdles and leaps for protein therapeutics.

Kozlowski S, Cherney B, Donnelly RP. Kozlowski S, et al. Among authors: cherney b. Ann N Y Acad Sci. 2009 Dec;1182:146-60. doi: 10.1111/j.1749-6632.2009.05158.x. Ann N Y Acad Sci. 2009. PMID: 20074283

10

Genetic basis of clarithromycin resistance in Bacillus anthracis.

Maxson T, Overholt WA, Chivukula V, Caban-Figueroa V, Kongphet-Tran T, Medina Cordoba LK, Cherney B, Rishishwar L, Conley A, Sue D. Maxson T, et al. Among authors: cherney b. Microbiol Spectr. 2024 Jun 4;12(6):e0418023. doi: 10.1128/spectrum.04180-23. Epub 2024 Apr 26. Microbiol Spectr. 2024. PMID: 38666793 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

70 results

Search Page

Filters